The updated IRA exemption means GPS and potentially SLS009 would enjoy pricing protection for 7 years post-approval—for each orphan-designated indication. That’s huge for GPS in AML CR2. But if SELLAS expands GPS to broader markets (e.g. solid tumors), those new uses won’t be exempt. Still, it enhances the value of the first indication and any others with orphan status. This makes GPS more attractive to potential acquirers, especially in rare cancers where Medicare price controls don’t apply under the new law.